Industry Briefs: Apr. 30, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: Apr. 30, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI has launched Smartsourcing sourcing options for its contract manufacturing and research services. Read More

AstraZeneca and The Medicines Company have entered into a global development and commercialization pact and have agreed to copromote Brilinta (ticagrelor), for treating acute ischaemic heart disease, in the United States. Read More

Baxter International has completed its purchase of Sigma International. Read More

Cetero Research has reached a final resolution with FDA over studies the company conducted in its Houston, Texas, bioanalytical laboratory between Apr. 1, 2005 through June 15, 2010. Read More

Covance and BML are expanding the companies’ jointly owned clinical-trial laboratory in Japan. Read More

GlaxoSmithKline and the University of Nottingham are collaborating to create a Center of Excellence for sustainable chemistry. Read More

Penn Pharma has invested in additional clinical and commercial packing capabilities. Read More

Teva has settled its patent-infringement litigation with Mylan in regards to Teva’s wakefulness product Nuvigil (armodafinil). Read More

Therapure has opened a custom biologics manufacturing facility. Read More

People News

AMRI has appointed Saravanakumar Dhakshinamoorthy as director of in vitro biology. Dhakshinamoorthy will report to Takeshi Yura, senior director of AMRI’s Singapore division. Read More

Watson Pharmaceuticals has announced changes in the company’s senior leadership. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here